147 related articles for article (PubMed ID: 38580594)
1. Severe asthma resistant to biological treatment?
Bascuas Arribas M; Camino Serrano M; Sanz Santiago V; López-Neyra A
An Pediatr (Engl Ed); 2024 May; 100(5):e9. PubMed ID: 38580594
[No Abstract] [Full Text] [Related]
2. Pediatric Severe Asthma in the Era of Biologic Treatments.
Teague WG
Pediatr Allergy Immunol Pulmonol; 2020 Sep; 33(3):118-120. PubMed ID: 32953228
[No Abstract] [Full Text] [Related]
3. Fractional Exhaled Nitric Oxide Nonsuppression Identifies Corticosteroid-Resistant Type 2 Signaling in Severe Asthma.
Couillard S; Shrimanker R; Chaudhuri R; Mansur AH; McGarvey LP; Heaney LG; Fowler SJ; Bradding P; Pavord ID; Hinks TSC
Am J Respir Crit Care Med; 2021 Sep; 204(6):731-734. PubMed ID: 34129808
[No Abstract] [Full Text] [Related]
4. Severe refractory asthma: an update.
Wener RR; Bel EH
Eur Respir Rev; 2013 Sep; 22(129):227-35. PubMed ID: 23997049
[TBL] [Abstract][Full Text] [Related]
5. Treatment of severe persistent asthma with IL-6 receptor blockade.
Esty B; Harb H; Bartnikas LM; Charbonnier LM; Massoud AH; Leon-Astudillo C; Visner G; Subramaniam M; Phipatanakul W; Chatila TA
J Allergy Clin Immunol Pract; 2019; 7(5):1639-1642.e4. PubMed ID: 30885880
[No Abstract] [Full Text] [Related]
6. Asthma treatment patterns in Dutch children using medication dispensing data.
Arabkhazaeli A; Vijverberg SJH; van der Ent CK; Raaijmakers JAM; Maitland-van der Zee AH
Pediatr Allergy Immunol; 2017 Sep; 28(6):606-608. PubMed ID: 28661552
[No Abstract] [Full Text] [Related]
7. Omalizumab Is Associated with Reduced Acute Severity of Rhinovirus-triggered Asthma Exacerbation.
Kantor DB; McDonald MC; Stenquist N; Schultz BJ; Smallwood CD; Nelson KA; Phipatanakul W; Hirschhorn JN
Am J Respir Crit Care Med; 2016 Dec; 194(12):1552-1555. PubMed ID: 27976938
[No Abstract] [Full Text] [Related]
8. Toward the optimal control of asthma.
Li JT
Mayo Clin Proc; 2009 Aug; 84(8):673-4. PubMed ID: 19648383
[No Abstract] [Full Text] [Related]
9. Biological treatment is approved for severe eosinophilic asthma.
Mayor S
BMJ; 2016 Nov; 355():i6472. PubMed ID: 27908911
[No Abstract] [Full Text] [Related]
10. Omalizumab in severe asthma: Evaluation of the clinical impact after its withdrawal.
D de Sousa M; Ferreira C; Arrobas A
Rev Port Pneumol (2006); 2017; 23(2):108-109. PubMed ID: 28209342
[No Abstract] [Full Text] [Related]
11. Pharmacological treatment of severe, therapy-resistant asthma in children: what can we learn from where?
Bush A; Pedersen S; Hedlin G; Baraldi E; Barbato A; de Benedictis F; Lødrup Carlsen KC; de Jongste J; Piacentini G;
Eur Respir J; 2011 Oct; 38(4):947-58. PubMed ID: 21737557
[TBL] [Abstract][Full Text] [Related]
12. Severity and control of severe asthma.
Bateman ED
J Allergy Clin Immunol; 2006 Mar; 117(3):519-21. PubMed ID: 16522449
[No Abstract] [Full Text] [Related]
13. Predominance of Atopic Asthma in Patients with Severe or Difficult-to-Treat Asthma in the TENOR-II cohort.
Haselkorn T; Mink D; Kianifard F; Ortiz B; Paknis B; Lecocq J; Chipps BE; Bleecker ER
Ann Allergy Asthma Immunol; 2021 Nov; 127(5):593-595. PubMed ID: 34391902
[No Abstract] [Full Text] [Related]
14. Real-life long-term omalizumab therapy in children with severe allergic asthma.
Deschildre A; Marguet C; Langlois C; Pin I; Rittié JL; Derelle J; Abou Taam R; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J
Eur Respir J; 2015 Sep; 46(3):856-9. PubMed ID: 26022964
[No Abstract] [Full Text] [Related]
15. Update on immunogenicity in severe asthma: Experience with mepolizumab.
Ortega HG; Meyer E; Brusselle G; Asano K; Prazma CM; Albers FC; Mallett SA; Yancey SW; Gleich GJ
J Allergy Clin Immunol Pract; 2019; 7(7):2469-2475.e1. PubMed ID: 30954640
[No Abstract] [Full Text] [Related]
16. Severe asthma and biologics: Data are good, listening to patients is better.
Bukstein DA; Guerra DG
Ann Allergy Asthma Immunol; 2021 Sep; 127(3):285-286. PubMed ID: 34479728
[No Abstract] [Full Text] [Related]
17. Omalizumab discontinuation in children with severe allergic asthma: An observational real-life study.
Deschildre A; Roussel J; Drumez E; Abou-Taam R; Rames C; Le Roux P; Pouessel G; Scalbert M; Bonnel C; Mitha S; Boileau S; Mordacq C; Thumerelle C; Labreuche J; Lejeune S; Marguet C
Allergy; 2019 May; 74(5):999-1003. PubMed ID: 30481388
[No Abstract] [Full Text] [Related]
18. Underestimating asthma severity--variability of classifications and outcomes.
O'Connor RD
Manag Care; 2004 Jul; 13(7 Suppl Reversing Asthma):3-8; discussion 17-9. PubMed ID: 18567140
[No Abstract] [Full Text] [Related]
19. Ambulatory management of pediatric asthma.
Gan VN; Gruchalla R
Respir Care Clin N Am; 2000 Mar; 6(1):87-133. PubMed ID: 10639559
[TBL] [Abstract][Full Text] [Related]
20. [Treatment resistant bronchial asthma. How should the pharmacists advise?].
Kenn K
Med Monatsschr Pharm; 2004 Apr; 27(4):123-7. PubMed ID: 15137588
[No Abstract] [Full Text] [Related]
[Next] [New Search]
